Adam Mead, PhD, completed his medical degree at the University of Oxford, Oxford UK. After completing his degree, he pursued a PhD at University College London, London, UK, focusing on the clinical impact of different types of FLT3 mutation in acute myeloid leukaemia.
In 2014, Prof. Mead set up his own research group which was funded by a clinical fellowship. He currently leads the NIHR MPN Studies Subgroup, which supervises myeloproliferative neoplasm (MPN) clinical research in the UK, and is also the Principal Investigator of over 28 clinical trials in MPNs.
Speaking on haematopoietic stem cell hierarchy in myeloid malignancies
Prof. Mead’s major area of research is understanding how the normal haematopoietic stem/progenitor hierarchy is disrupted during the development of myeloid malignancies. His aim is to improve management of myeloproliferative neoplasms (MPN), chronic myeloid leukaemia (CML) and other related conditions through incorporating an improved classification and restorative targeting of malignant stem and progenitor cell populations.